Stock SGMO SANGAMO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.5178 USD +2.94% Intraday chart for Sangamo Therapeutics, Inc. +1.23% -4.69%
Mar. 22 Sangamo Therapeutics Prices $24 Million Registered Direct Offering MT
Mar. 14 Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says MT

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vaxcyte Names Chief People Officer
MT
Adverum Biotechnologies Names R. Andrew Ramelmeier Chief Technology Officer
MT
Sangamo Therapeutics, Inc. Appoints Lisa Rojkjaer as Chief Medical Officer
CI
Sangamo Therapeutics, Inc. Announces Executive Changes
CI
Sangamo Therapeutics, Inc. Announces Directors Appointment
CI
Sangamo Therapeutics, Inc Announces Executive Changes
CI
Saira Ramasastry Decides Not to Stand for Re-Election as A Member of the Board of Directors of Sangamo Therapeutics, Inc
CI
Sangamo Therapeutics, Inc. Announces Board Changes, Effective March 1, 2022
CI
Sangamo Therapeutics, Inc. Appoints D. Mark Mcclung as Chief Operating Officer
CI
Sangamo Therapeutics, Inc. Announces Resignation of Gary H. Loeb as Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer
CI
Sangamo Therapeutics Appoints Prathyusha Duraibabu as Senior Vice President, Effective June 1, 2021
CI
Sangamo Therapeutics, Inc. Appoints Prathyusha Duraibabu as Principal Financial Officer
CI
Sangamo Therapeutics, Inc. Announces Executive Changes
CI
Sangamo Therapeutics, Inc. Announces the Resignation of Sung Lee as Executive Vice President, and Principal Financial Officer, Effective on February 1, 2021
CI
Sangamo Therapeutics, Inc. Announces Board Changes
CI
Sangamo Therapeutics, Inc. Announces Resignation of Adrian Woolfson as Executive Vice President of Research and Development
CI
Sangamo Therapeutics, Inc. Announces Executive Changes
CI
Sangamo Therapeutics, Inc. Announces Board Changes
CI
Sangamo Therapeutics, Inc. Announces Executive Changes
CI
Sangamo Therapeutics Appoints John Markels as Board of Director
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGMO Stock
  4. News Sangamo Therapeutics, Inc.
  5. Insiders